Lawrence Blonde
Endocrinology, Diabetes & Metabolism · New Orleans, LANPI 1821055237
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Novo Nordisk at 52.2% of the total. Reporting peaked in 2019 at $57,960 and has fallen 80.6% since, to $11,233 in 2025. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $957.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$74K
- Sanofi-aventis U.S. LLC$37K
- Corcept Therapeutics$11K
- Gilead$4K
- Mannkind Corporation$4K
- Merck$4K
- plus $8K from 6 others
Across 60 payments — averaging $1423.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$33K
- Janssen Scientific Affairs, LLC$20K
- Bayer$16K
- Boehringer Ingelheim International GmbH$8K
- Eli Lilly$7K
- Corcept Therapeutics$1K
What the payments were for
- Consulting fees$77,11454%
- Speaking & faculty fees$35,45225%
- Travel & lodging$25,87418%
- Food & beverage$3,2072%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $73,908 |
| Sanofi-aventis U.S. LLC | 61 | $36,562 |
| Corcept Therapeutics | 16 | $11,357 |
| Gilead | 7 | $4,134 |
| Mannkind Corporation | 5 | $4,027 |
| Merck | 3 | $3,675 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $3,540 |
| AstraZeneca | 1 | $2,000 |
| Boehringer Ingelheim International GmbH | 6 | $1,519 |
| Eli Lilly | 5 | $861 |
| Astrazeneca UK Limited | 1 | $96 |
| Bayer | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$30,259
- SOLIQUA 100/33$19,514
- TOUJEO$13,652
- Ozempic$11,431
- Korlym$11,195
- NO PRODUCT DISCUSSED$4,882
- AFREZZA$4,027
- CYCLOSET$3,540
- JARDIANCE$1,379
How this compares
$141,712 in reported general payments places this provider in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Other endocrinology, diabetes & metabolism in New Orleans
- Vivian FonsecaNew Orleans$658K
- Dragana LovreNew Orleans$14K
- Bryan GrissettNew Orleans$8K
- Melina Roman-GerardinoNew Orleans$7K
- Mariam MenhemNew Orleans$5K
- Nyrene HaqueNew Orleans$5K
- Sarah SternliebNew Orleans$2K
- Suneeta GanjiNew Orleans$2K
- Timothy GilbertBaton Rouge$985K
- Abdul KhanHammond$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.